Non-Small Cell Lung Cancer (NSCLC) — Research Intelligence Dashboard
Prototype dashboard for architecture validation. Metrics shown are illustrative until registry enrichment and GRMI calculation engine are live.
Executive Summary
Data snapshot: February 2026
605
Total Active Trials
ClinicalTrials.gov Registry Subset
187
New Trials
Rolling 12 Months
23.5%
Phase I Density
Percentage
34
Distinct Biomarkers
Active
Accelerating
Research Momentum Classification (Rolling 12-Month Model)
Global Research Momentum Index (GRMI)
87
GRMI ScoreComposite index weighted as:
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
Accelerating
12-Month Trend
Component Breakdown
92
Trial Velocity Score
85
Early Phase Density
88
Biomarker Diversity
81
Modality Expansion
89
Geographic Spread
Phase & Modality Distribution
Phase Distribution
Modality Distribution
Geographic Spread
47
Countries Active
298
United States
Active Trials
189
Europe
Active Trials
118
Asia-Pacific
Active Trials
12-Month Geographic Expansion:+9 new countries, +67 new trial sites
Centers Actively Studying This Area
Institutions listed based on active NSCLC trial count ≥ 25 (ClinicalTrials.gov registry analysis).
| Institution Name | Active NSCLC Trials | Phase I % | Dominant Modality | Distinct Biomarkers |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 47 | 34% | Targeted Therapy | 18 |
| MD Anderson Cancer Center | 52 | 38% | Immunotherapy | 22 |
| Dana-Farber Cancer Institute | 39 | 29% | Combination | 16 |
| University of California, San Francisco | 34 | 41% | Targeted Therapy | 19 |
| Johns Hopkins Hospital | 31 | 32% | Immunotherapy | 14 |
| Mayo Clinic | 29 | 27% | Combination | 13 |
Institutional Research Footprint Overlay
Institutional Overlay (Phase II Modeling)
This section will display global baseline vs. selected institution metrics side-by-side, enabling comparative analysis of institutional research positioning.
What This Signals
Early-phase activity accelerating
Phase I density increased 4.2 percentage points over 12 months
Biomarker diversification increasing
34 distinct biomarkers active, up from 27 in prior year
Modality shift emerging
ADC and bispecific antibody trials increased 67% year-over-year
Geographic expansion detected
9 new countries initiated NSCLC trials in past 12 months